News

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with ...

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) ...